Why sterile injectables dominate shortage lists

On Oct. 30, 2026, FDA's drug shortage database, as published through openFDA¹, listed 69 drugs in current shortage. Forty-nine of them, or 71 percent, were injections. The list reads like a hospital supply room: dextrose solutions, sodium bicarbonate, lidocaine, heparin, sterile water for injection, and older cancer drugs such as carboplatin and methotrexate. Tablets and capsules of every kind accounted for 10.

Injectable shortages also last longer. In GxRadar's analysis of the same data, the median current injectable shortage was first posted about 2,005 days earlier, roughly five and a half years, against about 1,306 days for the other forms. Seventeen of the 49 injections were first posted before 2020. Lidocaine injection's entry dates to 2012, sodium bicarbonate's to March 2017 and heparin's to November 2017.

None of this is new. Each time federal researchers have looked, in FDA's 2019 root-cause report and three HHS analyses, they have found sterile manufacturing that fails in specific ways and only a few producers for each drug. Prices are often too low to make adding capacity worth a company's while. The full current list, with dates, is on the GxRadar shortage tracker.

Fifteen years of the same pattern

A 2011 ASPE brief⁵ said sterile injectables are a small share of the overall drug market but a disproportionate share of drugs in shortage, and that they include critical drugs such as cancer treatments and emergency medicines. FDA's 2019 analysis² of 163 shortage drugs found the typical one had been on the market almost 35 years. GxRadar's explainer on how FDA tracks shortages describes how drugs get onto and off that list.

Why sterile manufacturing breaks down

Injectable drugs must be sterile, and FDA's guidance on aseptic processing⁴ warns that a nonsterile product can pose a life-threatening risk to patients. The guidance describes two ways to make one. In terminal sterilization, the product is filled and sealed in a clean environment and then sterilized in its final container, usually with heat or irradiation. In aseptic processing, the drug, the container and the closure are sterilized separately and then brought together. Because nothing sterilizes the sealed product afterward, the filling has to happen in an extremely clean environment.

FDA says aseptic processing involves more variables than terminal sterilization. Glass vials may go through dry heat, rubber stoppers through moist heat, and the liquid through filtration, and each step must be validated and controlled. Any manual handling during assembly is a contamination risk. In the critical filling zone, the guidance sets air quality⁴ at no more than 3,520 particles of 0.5 micrometers or larger per cubic meter, the level known as ISO 5 or Class 100. FDA also states that sterile drugs should be made by aseptic processing only when terminal sterilization is not feasible.

That strict standard is what makes supply fragile. HHS's 2024 white paper⁷ notes that most shortages follow quality-related breakdowns in manufacturing, and the manufacturer must fix the problem before production can resume. FDA's 2019 report² found that 62 percent of shortage drugs went short after manufacturing or quality problems, and the agency's reviews have pointed to issues such as particulates and lapses in sterility assurance. The rules investigators apply are covered in GxRadar's CGMP explainer, and sterility and contamination problems are the largest reason category on the GxRadar recalls page.

Few makers, specialized lines

FDA's shortage FAQ³ describes the structure directly. Fewer firms make older sterile injectables, a limited number of production lines can make them, and the raw material suppliers have limited capacity too. With long lead times and complex processes, when one company has a problem or stops making a drug, the others struggle to raise output quickly.

Concentration shows up in the numbers.

• In ASPE's 2011 review⁵ of 33 generic sterile injectable cancer drugs, at least 90 percent of 2010 unit sales came from three or fewer manufacturers for 28 of them.
• Those manufacturers each ran from one to 10 injectable plants, and some drugs, including cytotoxic cancer drugs, can only run on certain types of lines.
• In July 2024, ASPE counted⁶ an average of five manufacturers per molecule for generic injectables and nine for generic oral drugs. The most crowded injectable molecule had 27 makers, compared with 57 for orals.

When one of a handful of plants stops shipping, the effect is national. The 2023 cancer drug shortage began that way, and carboplatin injection, first posted as short on April 28, 2023, was still listed as a current shortage in the October 2026 openFDA data¹.

Low prices, uneven returns

Older injectables sell for little. In FDA's 2019 sample², the median price per injection in the year before a shortage was $11.05, adjusted to 2018 dollars. That is a historical benchmark from FDA's analysis and does not describe current prices.

A December 2024 ASPE brief⁶ estimated returns on generic injectables launched between July 2018 and July 2021. ASPE did not have company cost data, so it modeled three cost scenarios. The table summarizes the results 36 months after launch.

Averages flatter the typical product. A handful of very profitable launches lift the market-wide return, while 70 percent of injectable entries in the middle scenario had not broken even after three years. ASPE noted⁶ that injectables probably cost more to make than oral generics because of specialized facilities, stricter sterility requirements and more complex formulation. It concluded the findings fit the theory that low expected profits produce a thinner, less resilient market, while warning that the cost estimates carry substantial uncertainty. For how competition pushes generic prices down in the first place, see why generic prices fall as competitors enter.

How hospitals buy

Most sterile injectables reach hospitals through group purchasing organizations and authorized wholesalers, according to ASPE's 2011 brief⁵. FDA's 2019 report² described contract terms that add pressure, including low-price clauses that let a purchasing group walk away if a competitor offers a lower price. HHS's 2024 white paper⁷ added that hospitals' own budget pressure can push them toward the lowest-cost source without enough attention to whether they end up relying on a single producer.

Inventory buffers are thin. In 2011, ASPE reported⁵ that one large injectable maker usually held three to four months of inventory and wholesalers about 30 days, while other makers had notified FDA of shortages with a month or less on hand.

Ingredients often come from far away. The HHS white paper⁷ cited estimates that 90 to 95 percent of generic sterile injectables used in critical acute care rely on key starting materials and drug substances from China and India. GxRadar's piece on onshoring covers the federal response to that dependence.

Proposals that have not yet become law

HHS's 2024 white paper⁷ focused on generic sterile injectables and floated two programs. A Manufacturer Resiliency Assessment Program, run through a public-private partnership, would score generic manufacturers on resilience. A Hospital Resilient Supply Program would set financial incentives or penalties tied to hospitals' purchasing behavior. FDA's 2019 report² had already recommended a quality maturity rating and contracts that reward reliable supply.

HHS said in the same paper⁷ that lasting solutions would require additional statutory authority and funding. For patients, injectable shortages mostly play out inside hospitals and clinics, and questions about how a shortage affects a specific treatment belong with the care team, including the pharmacist.